A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

NCT00642018 ↗

Phase 2 Completed 154 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.

Timeline

Start: 2008-03
Primary completion: 2011-08
Completion: 2012-04

Publications

de Liano AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GATAPARSEN	Antisense oligonucleotide	—	—
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	5 mg	Oral

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications